Keywords: Hypertension, Telmisartan, Amlodipine, Valsartan, Novartis, Market, USA, Europe, Fixed-dose combinations

Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013

Article | 08 January 2010

A hypertension drug that requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan) would earn 30% patient share according to surveyed US ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in